Reporting owner · Q3 2026 · CIK 1856565

Oelschlager Kristen M: insider trades.

Oelschlager Kristen M reported 11 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 10 sales ($1.4M), across 1 company.

Transactions
11
Purchases (P)
0
Sales (S)
10
Companies
1
Name as filed
Oelschlager Kristen M

Companies

CompanyRelationshipTransactions
Castle Biosciences Inc (CSTL)Officer · Chief Operating Officer11

Transactions

11 non-derivative rows. Shares and prices as filed.
DateCompanyCodeSharesPriceOwned afterFiling
2026-09-01Castle Biosciences IncS200$34.0213,356Form 4
2026-09-01Castle Biosciences IncS3,952$33.3613,556Form 4
2026-09-01Castle Biosciences IncM4,152$3.3817,508Form 4
2026-08-25Castle Biosciences IncS7,161$34.2677,872Form 4
2026-08-25Castle Biosciences IncS5,223$34.6472,649Form 4
2026-08-24Castle Biosciences IncS12,218$33.6985,033Form 4
2026-08-03Castle Biosciences IncS1,100$30.6213,288Form 4
2026-08-03Castle Biosciences IncS3,000$29.1218,874Form 4
2026-08-03Castle Biosciences IncS4,486$3014,388Form 4
2026-07-01Castle Biosciences IncS8,186$24.422,274Form 4
2026-07-01Castle Biosciences IncS400$24.7821,874Form 4

Questions

What stock did Oelschlager Kristen M buy or sell?

Oelschlager Kristen M reported 11 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 10 sales ($1.4M), across 1 company.

Is Oelschlager Kristen M the same person as other filers with this name?

This page covers SEC CIK 1856565 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.

Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.

Plain-text version for agents and LLMs: /insiders/oelschlager-kristen-m-1856565.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.